Novel lipid (mannito-stearate) antiviral nucieoside and oligonucleotide conjugates were prepared with improved lipophilic and membrane associating properties of drugs. Potential advantages of these liponucleotide prodrugs are lower toxicity, increased cellular uptake, nuclease resistivity and antiviral activity. Oligonucleotide conjugate complementary to a unique segment of viral genome may selectively disrupt the processes dependent on the segment by hybridisation.
INTRODUCTION
To date the only clinically approved drug for treating AIDS is .Thus, new strategies are needed to develop compounds which will selectively attack HIV infection and replecation. These novel anti HIV agents should have improved nuclease resistivity and cellular transport characteristics. At the sametime they should be devoid of undesirable systemic toxicity associated with many nucieoside analogues currently being used or evaluated. A prelude to structure activity relationship, the ester linkage is important because, this bond is readily hydrolysed during metabolic processes of the body. It is anticipated that the liponucleotides will be taken up in large proportions by macrophages henceforth they can be proved as a promising agent with a special potential to target drugs to the macrophage reservoir of HIV infection, Thereby reducing the toxicity of the antiviral nucieoside to other cells. We have designed synthesized and evaluated the combination of a novel phosphate analogue with AZT for DNA anti HIV-I activity, nuclease resistivity, toxicity, and cellular uptake and hybridization arrest.
RESULTS AND DISCUSSION
The object of the present study is to develop and evaluate innovative strategies for selectively attacking the viral etiologic agents of AIDS with novel lipid analogues that are membrane interactive and have potential anti HIV-I activity. Lipids are lipophilic that accumulate in the plasma membrane of T-lymphocytes and monocytes /macrophages (cells which serves as important reservoirs of latent and active HIV infections) and undoubtedly cross blood -brain barrier in the host. The discovery of a new class of biologically active nucleosides, which provides extra stability to duplex when incorporated into oligonucleotides 3 ' 4 , led us to synthesize and evaluate this mannito-stearate conjugates of AZT and of DNA. In our chemically modified units hydrophlic group or the polar head group are DNA strand with anionic phosphate backbone and AZT respectively. Whereas, the lipophilic domain will be cationic lipid in both the units. Mannito-stearate a novel phospholipid analogue was covalentely linked to anti HIV nucieoside and to sequence specific oligodeoxynucleotide by solid phase synthesis. Comparative studies of Tm's, toxicity, nuclease resistivity, antiviral activity and cellular uptake of these chemically modified analogues with that of unmodified were also carried out.
EXPERIMENTAL
Prior purified mannitol was selectively tritylated to get monotrityl derivative. This monotritylated mannitol was then esterified with stearyl chloride, which in its turn was prepared from stearic acid and thionyl chloride. The resulting compound was then detritylated by treating with TCA in DCM. This detritylated derivative was converted to corresponding H-phosphonate, viz. 1,2,3,4,5-penta-ohexadecyl mannito-6H-phosphonte, by standard procedure and was conjugated with previously synthesised sequence specific oligomer (Fig 1) and AZT (Fig 2) , by a final coupling cycle in pyridine / acetonitrile. The products were then oxidised with I 2 and deblocked normally. Since the sequence of oligomer (ACACCCAA) was complementry to a unique segment of a viral genome, therefore, its complementry sequence (TTGGGTGT) was also synthesized for melting studies to find out the extent of hybridisation. These conjugates were characterised by HPLC, TLC, PAGE, Thermal dissociation curves for hybrids formed with complementry strands, UV and NMR spectroscopy. 
CONCLUSION
Several conclusions may be drawn from the datas collected. Anchoring a novel phospholipid analogue (mannito-stearate) to the sequence specific oligonucleotide and antiviral nucleoside (AZT), (i) significantly enhances the antiviral activity in vitro, (ii) has minor effect on the stability of hybrid duplex nucleus resistivity, (iii) increases nuclease resistivity in case of DNA conjugate, whereas decreases incase of AZT conjugate, (iv) yields 8-10 times more cell associated counts than unmodified, (v) reduces the cell toxicity 5-10 fold. HIV-1 inhibition assays are still in progress and unusual activity is expected which will make such amphiphilic bioconjugates promising targets for further study as potential therapeutic agents in the treatment of AIDS and related viral diseases.
